A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers / 南方医科大学学报
Journal of Southern Medical University
;
(12): 943-945, 2009.
Artículo
en Chino
| WPRIM
| ID: wpr-268804
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with trastuzumab for HER2 positive breast cancers.</p><p><b>METHODS</b>PubMed online database, ASCO abstract database, SABCS abstract database, ESMO abstract database and CBMdisc database were searched for literatures related to trastuzumab in neoadjuvant chemotherapy for breast cancers. A meta-analysis was performed for retrieved literatures meeting the inclusion criteria.</p><p><b>RESULTS</b>Three clinical trials were included. Meta-analysis showed that compared to chemotherapy only, regimens combined with trastuzumab could significantly improved the pCR rate of HER2-positive breast cancers (RR=1.65, 95% CI 1.28-2.13, P<0.0001) without increasing the frequencies of cardiac toxicity (RR=1.16, 95% CI 0.82-1.64, P=0.41).</p><p><b>CONCLUSION</b>In neoadjuvant chemotherapy for HER2-positive breast cancers, chemotherapy combined with trastuzumab is superior to exclusive chemotherapy.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias de la Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Ensayos Clínicos Controlados Aleatorios como Asunto
/
Receptor ErbB-2
/
Terapia Neoadyuvante
/
Usos Terapéuticos
/
Quimioterapia
/
Anticuerpos Monoclonales Humanizados
/
Trastuzumab
/
Genética
Tipo de estudio:
Ensayo Clínico Controlado
/
Revisiones Sistemáticas Evaluadas
Límite:
Femenino
/
Humanos
Idioma:
Chino
Revista:
Journal of Southern Medical University
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS